Bukwang Pharmaceutical Expands Clinical Trials of COVID-19 Treatment 'Rebovir'

[Asia Economy Reporter Kim Ji-hee] Bukwang Pharmaceutical announced on the 13th that it will expand the clinical trial scale of its COVID-19 treatment candidate Levovir from 40 to 80 participants.

Bukwang Pharmaceutical stated, "The data from the COVID-19 treatment clinical trial (CLV-201) completed last February is currently under analysis, and the official final data analysis has not been completed yet," but added, "Among the evaluation variables, we confirmed that the Levovir treatment group showed a tendency for a reduction in the amount of the COVID-19 virus (SARS-CoV-2) compared to the placebo group in terms of viral load reduction." They further added, "Based on this, we decided to expand the ongoing clinical trial (CLV-203)."

Bukwang Pharmaceutical plans to enhance the reliability of the data by increasing the number of patients in the second clinical trial (CLV-203), which measures the reduction of live virus load in mild to moderate cases, from 40 to 80 participants to obtain clearer results on virus reduction. Since most of the target 40 patients in the original protocol were recruited within about three weeks after the start of recruitment, additional recruitment is also expected to proceed quickly.